MANE

119.5203.92%
MN

Mark Neumann

Chief Commercial & Strategy Officer

Mr. Mark Neumann is Chief Commercial and Strategy Officer of Veradermics, Incorporated from December 2025. Mr. Neumann was Executive Vice President, Chief Commercial Officer of Intra-Cellular Therapies, Inc since October 16, 2018 until April 2025. Mr. Neumann previously worked at amgen where he was initially recruited as Vice President, Marketing to build and establish a new U.S. cardiovascular business unit and launch Amgen’s first ever cardiovascular medicines. In his most recent role as Vice President, Global Marketing from June 2014 to October 2018 with leadership of nephrology, inflammation and bone health, Mr. Neumann was responsible for conceiving therapeutic area strategies, developing marketing platforms for global launches and directing commercial assessments for external business development opportunities. Before Amgen, from February 2014 to June 2014, Mr. Neumann served in a leadership position at AstraZeneca. Before joining AstraZeneca, from June 1988 to February 2014, he served at Bristol Myers Squibb Company in positions of increasing responsibility, including commercial leadership roles and held senior U.S. and global commercial roles in neuroscience, cardiovascular and diabetes. During his tenure at BMS he led sales and marketing for the U.S. neuroscience business unit and delivered strong growth of the antipsychotic Abilify. He also held the position of Vice President, Global Commercialization for neuroscience where he established a new worldwide disease area strategy and directed the commercialization of neuroscience pipeline assets. Mr. Neumann is a licensed Certified Public Accountant (inactive). Mr. Neumann received his B.A. in Economics and Business Administration from Lafayette College.

Positions